english.prescrire.org > Spotlight > Archives : 2022 > In the September issue of Prescrire International: late-onset neutropenia linked to rituximab (Mabthera° or other brands)

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

In the September issue of Prescrire International: late-onset neutropenia linked to rituximab (Mabthera° or other brands)

FREE DOWNLOAD Among 104 reports to French regional pharmacovigilance centres involving severe late-onset neutropenia linked to rituximab, the time to onset varied from 1.5 to 15 months after the last dose. These cases of neutropenia expose patients to a risk of serious infections.
Full text available for free download.

  • Rituximab (Mabthera° or other brands) is a monoclonal antibody used as a cytotoxic drug in some types of haematological cancer, and as an immunosuppressant, particularly in rheumatoid arthritis and pemphigus vulgaris.

  • Several French regional pharmacovigilance centres identified and then analysed reports in the French pharmacovigilance database concerning neutropenia attributed to rituximab.

Full text available for free download below.

©Prescrire 1 September 2022

Source: "Rituximab: late-onset neutropenia, sometimes more than 6 months after stopping treatment (continued)" Prescrire International 2022; 31 (240): 214. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:
"Rituximab - Mabthera° or
other brands. Pemphigus
vulgaris: more patients
in remission than with
other immunosuppressants,
lower exposure to
corticosteroids, but
a risk of cancer"
(May 2021)
Free

Numerous other texts
available via the "Search"
function, using the keyword
"rituximab"
Search


Read more:

All the subjects in
Prescrire's Spotlight
Free >